Healthcare risks in general, and those related to medication errors in particular, constitute a serious problem with consequent human, medical, and economic repercussions which healthcare authorities are recognizing and addressing as priority matters in some countries. However, though the magnitude of the problem is similar in Spain, this country has yet to become fully aware of the transcendence of the situation. Risk management activities in healthcare centers are presently evolving as risk managers adopt preventive and proactive approaches requiring the collaboration of other healthcare professionals in developing risk reduction programs, including those focused on medication error prevention. This article briefly describes the principal bases for safety improvement strategies, and outlines a risk management program for medication error prevention in hospitals. In short, it is assumed that risk managers form part of a team whose job it is to analyze incidents when they occur, use this information to establish actions for improving healthcare services through risk reduction, and ensure that the principles of risk management form an integral part in the activities and the culture of organizations. The final result of risk management is the establishment and maintenance of significant system changes which enhance the quality of healthcare services and achieve greater patient safety.
Download full-text PDF |
Source |
---|
J Med Case Rep
January 2025
Division of Orthopedic Surgery, Hillel Yaffe Medical Center, Ha-Shalom St, 3820302, Hadera, Israel.
Background: Low-grade fibromyxoid sarcoma is a rare soft tissue tumor characterized by a benign histological appearance but with a high potential for recurrence and metastasis. First described by Evans in 1987, recurrence and metastasis can occur decades after the initial diagnosis, complicating long-term management.
Case Presentation: We report the case of an 83-year-old Jewish female patient diagnosed with low-grade fibromyxoid sarcoma in her right shoulder.
BMC Med
January 2025
Health Emergencies Programme, World Health Organization, Geneva, Switzerland.
Background: Tecovirimat, an antiviral treatment for smallpox, was approved as a treatment for mpox by the European Medicines Agency in January 2022. Approval was granted under "exceptional circumstances" based on effectiveness found in pre-clinical challenge studies in animals and safety studies in humans showing minimal side effects. As clinical efficacy studies are still ongoing, there is currently limited information with regard to the acceptability of tecovirimat to treat mpox.
View Article and Find Full Text PDFBMC Med
January 2025
Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Haidian District, 38 Xueyuan Road, Beijing, 100191, China.
Background: Diet is a well-known determinant of mental health outcomes. However, epidemiologic evidence on salt consumption with the risk of developing depression and anxiety is still very limited. This study aimed to examine the association between adding salt to foods and incident depression and anxiety longitudinally.
View Article and Find Full Text PDFBMC Oral Health
January 2025
Qingdao Municipal Hospital, Shandong, 266071, China.
Background: Lip behaviors can lead to maxillofacial developmental disorders such as anterior open bite, posterior crossbite, increased overjet, and a higher risk of developing a Class II malocclusion. However, lip-sucking, a behavior often underreported and overlooked, may adversely affect the periodontal health of permanent teeth in adolescents under extreme conditions if not promptly identified and managed.
Case Presentation: We report a unique case of an 11-year-old boy with a severe periodontal-endodontic lesion on tooth 32, caused by prolonged, high-frequency, and high-intensity lip sucking.
BMC Med
January 2025
Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK.
Background: Polypharmacy (i.e., treatment with ≥ 5 drugs) is common in patients with atrial fibrillation (AF) and has been associated with suboptimal management and worse outcomes.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!